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Objective:Wedescribe a case of tumor induced osteomalacia (TIO) in a patientwith a ﬁbroblast growth factor 23
(FGF-23) secreting anaplastic thyroid carcinoma. The current imaging modalities are reviewed.
Design and intervention: Clinical, biochemical, and radiological assessments were done, including computer to-
mography (CT) of the neck and skull to thigh positron emission tomography (PET)/CT. The patient underwent
surgical tumor debulking three days after presentation due to airway compromise. Molecular studies of the
resected tissuewere performed using reverse transcriptase–polymerase chain reaction (RT-PCR) and gel electro-
phoresis for the phosphaturic mesenchymal tumor FGF-23.
Results: Resected tissue demonstrated features of anaplastic thyroid cancerwith positivemarkers for FGF-23 pro-
tein, consistentwith a FGF-23 secretingparaneoplastic tumor. The patient'smetastatic burden rapidlyprogressed
as demonstrated by a dramatic rise in serum FGF-23 levels and worsening hypophosphatemia in concert with
progression of the metastatic lesions on PET/CT.
Conclusion:We believe that our patient's rapidly progressive anaplastic thyroid cancer was responsible for per-
sistent hypophosphatemia and osteomalacia, substantiated by the ﬁnding of FGF-23 protein within the thyroid
tumor cells. Our case indicates that anaplastic thyroid cancer can cause TIO.







Tumor induced osteomalacia (TIO) is a rare phosphorus-wasting
syndrome caused by tumors capable of secreting FGF-23 in a similar
fashion as other FGF-23-mediated diseases, such as x-linked
hypophosphatemia, autosomal recessive and autosomal dominant
hypophosphatemia rickets. TIO is characterized by signs and symptoms
of severe osteomalacia or rickets. Clinical features include bone and
muscle pain, muscle weakness, skeletal deformities and recurrent frac-
tures as well as microfractures of long bones (Drezner, 2008; Mammen
and de Beur SM, 2008). Laboratory testing usually reveals low serum
phosphorus, lowor inappropriately normal range circulating concentra-
tion of 1,25-dihydroxyvitaminD (1,25(OH)2D), high urine fractional ex-
cretion of phosphorus, normal serum calcium and normal 25-
hydroxyvitamin D 25(OH)D levels. Successful surgical resection of the
FGF-23 secreting tumor is curative, thus accurate localization of the
tumor is of the utmost importance (Jonsson et al., 2003). The majority
of the TIO cases previously reported in the literature have been caused
by small mesenchymal tumors derived from bone (Fatani et al., 2013;iabetes and Metabolism, Mayo
nited States.
en access article under the CC BY-NCWesterberg et al., 2012; Gandhi et al., 2012), soft tissue (Jiang et al.,
2012), skin (Gardner et al., 2013) and cartilage (Hautmann et al.,
2014). TIO has also been reported in association with malignant adeno-
carcinomas of the ovary (Lin et al., 2014), lung (Taylor et al., 1984), pros-
tate (Lee et al., 2014), colon (Ryan and Reiss, 1984) and head/neck
(Tarasova et al., 2013; Kominek et al., 2011; Luo et al., 2013; Mathis
et al., 2013). To our knowledge, TIO induced by anaplastic thyroid can-
cer has not been reported previously.
2. Case report
A 59 year-old white man presented to theMayo Clinic Florida emer-
gency department with a 3-month history of rapidly progressive dys-
phagia to liquids and solids, cough and hoarseness. CT of the neck
with contrast revealed a 7 cm inﬁltrating mass centered in the
anteroinferior aspect of the neck that completely encased the left carot-
id artery, esophagus and trachea (Fig. 1). Hewas evaluated by an otolar-
yngologist who performed a core needle biopsy of the mass, which
demonstrated ﬁndings of an undifferentiated malignant neoplasm.
Due to extensive inﬁltration of vital structures, a complete resection of
the tumor was not possible. The patient underwent debulking of the
tumor, tracheotomy for airway management and gastrojejunostomy-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Axial CT contrast-enhanced image at the level of the upper trachea demonstrates a
large soft tissue density mass in the anterior neck centered to the left of midline,
compatible with the patient's known history of anaplastic thyroid cancer. The mass
completely encases the left carotid artery (arrowhead), trachea and esophagus and
obliterates the left jugular vein. The tracheal ring (fat arrow) is partially destroyed with
tumor inﬁltration into the tracheal lumen. A portion of the tracheostomy tube (curved
arrow) is seen just superior to its tracheal entry site.
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consistent with anaplastic thyroid carcinoma.
His past medical history was signiﬁcant for papillary thyroid cancer
treated with right lobectomy in 1984. He underwent completion thy-
roidectomy in 1991due to a recurrence. Hedeveloped vocal cord immo-
bility after his ﬁrst surgery. He appears to have mild post surgical
hypoparathyroidism based on ﬁnding of low calcium with low normal
PTH and high urine calcium. The patient was placed on hormone re-
placement therapy for expected hypothyroidism. The patient was un-
sure whether he underwent 131I therapy at the time of his second
surgery. His phosphorus level prior to presentation is unknown.
During his hospitalization, the patient required large amounts of
daily phosphorus replacement due to persistent critically low serum
phosphorus levels. Biochemical evaluation (Table 1) was also notewor-
thy for elevated 24 h urine phosphorus secretion, low serum
1,25(OH)2D, and increased serum alkaline phosphatase activity. The
serum 25(OH)D level was in the lower end of the reference range.
Laboratory ﬁndings are listed in Table 1. A skull-thigh PET/CT
showed abnormal areas of hypermetabolism consistent with metasta-
ses in the lungs, mediastinum, liver and left greater trochanter. RepeatTable 1
Results of laboratory tests.
3/19 3/22 4/11 Normal range
Serum values
Calcium (mg/dl) 8.8 8.6 8.8 (8.9–10.1)
Phosphorus (mg/dl) 0.7 0.9 0.9 (2.5–4.5)
ALP (IU/I) 128 146 649 (45–115)
Creatinine (mg/dl) 0.7 0.8 1.1 (0.8–1.3)
BUN (mg/dl) 7 11 28 (8–24)
Intact PTH (pg/ml) 16.1 9.9 (15–65)
1,25(OH)2D (pg/ml) 17 b8 (18–78)
25(OH)2D (ng/ml) 12.2 17.3 (N20)
TSH (mIU/L) 38.17 45.34 19.32 (0.3–5)
Free T4 (ng/dL) 1.1 0.8 (0.8–1.8)
TG (ng/ml) 13.4 (b0.1)a
TG Ab (Iu/mL) b1.8 (b1.8)
iFGF-23 (RU/mL) 2355 7950 (b180)
Urine values
Calcium (mg/24 h) 391 636 (25–300)
Phosphorus (mg/24 h) 1169 3591 (b1099)
ALP- total alkaline phosphatase; TG- thyroglobulin tumor marker; TG Ab- thyroglobulin
antibody.
a Athyrotic individuals; iFGF 23- intact ﬁbroblast growth factor 23.imaging one week later revealed progression in size and number of
his lung and liver metastases (Fig. 2). Biopsy of these lesions was not
feasible due to the decline of patient's health status.
The patient suffered a rapid decline in his overall condition and died
of multiorgan failure one month after presentation. A repeat FGF-23
level at the time of his death had more than tripled from 2355 RU/mL
to 7950 RU/mL.3. Pathology and immunohistochemistry
Tissue obtained from the anterior left neck measuring 6.0 cm in
maximumdimensionwas provided for pathological analysis. Dissection
revealed a 3.5 cm gray/white tumor with adherent soft tissue and skel-
etal muscle. Histologically, a malignant epithelioid and spindle cell
tumor was identiﬁed that was inﬁltrating the skeletal muscle and
encasing the large vessel walls. The tumor was negative for cytokeratin,
thyroglobulin and TTF-1, consistent with an anaplastic thyroid carcino-
ma. Tissue fragments obtained during surgical debulkingwere analyzed
using reverse transcriptase polymerase chain reaction (RT-PCR) and gel
electrophoresis for phosophaturic mesenchymal tumor FGF-23 gene on
RNA extracted from parafﬁn imbedded tissue. The tissue was positive
for the presence of FGF-23 by RT-PCR (Fig. 3). The FGF-23 gene revealed
positive ampliﬁcation results; all controls yielded appropriate results.
Molecular analysis conﬁrmed the expression of the gene within the
neoplastic cells.Fig. 2. Coronal fused PET/CT image demonstrates abnormal glucose hypermetabolism of a
large superior mediastinal mass (arrow) corresponding the patient's known anaplastic
thyroid cancer. There is abnormal hypermetabolism in the visualized mediastinal and
bilateral hilar lymph nodes (arrowheads), compatible with metastatic disease.
Fig. 3. RT-PCR gel of the FGF-23 tumor and the controls.
83E.G. Abate et al. / Bone Reports 5 (2016) 81–854. Discussion
TIO (also known as oncogenic osteomalacia) is a bone mineraliza-
tion disorder caused by secretion of a phosphorus-wasting protein,
FGF-23 from tumor cells (Jonsson et al., 2003; Shane et al., 1997; Cai
et al., 1994). FGF-23 is detectable in the blood of normal individuals,
but is markedly increased in cases of tumor-induced TIO due to overex-
pression of FGF-23messenger RNA (mRNA) (Jonsson et al., 2003). TIO is
most often caused by small benign tumors of mesenchymal origin, such
as osteoblastomas, nonossifying and ossifying ﬁbromas (Drezner, 2008;
Mammen and de Beur SM, 2008). Less commonly, TIO manifests as a
paraneoplastic syndrome derived from various malignant tumors. In
most reported cases, complete surgical resection of the inciting tumor
results in absolute resolution of the signs and symptoms of TIO. Further-
more, Shane et al foundbone remineralization on iliac biopsy samples in
patients who had undergone complete surgical resection (Shane et al.,
1997). Although the syndrome has been reported in children, TIO typi-
cally affects adults. Importantly, TIO patients do not have a history of
childhood fractures nor a family history of hypophosphatemia or osteo-
malacia, which help distinguish this entity from other phosphorus-
wasting syndromes such as x-linked hypophosphatasia and autosomal
dominant and autosomal recessive hypophosphatasia. The diagnosis
of TIO is conﬁrmed by documentation of an elevated serum FGF-23
level (Carpenter TO et al., 2011).
Themechanismbywhich FGF-23 is involved in phosphorus-wasting
is well described (Shane et al., 1997; Cai et al., 1994; Carpenter TO et al.,
2011). FGF-23 is a member of the ﬁbroblast growth factor family re-
sponsible for phosphorus metabolism and is produced as a hormone
by osteocytes and osteoblasts. Excess secretion of FGF-23 causes
hypophosphatemia and impaired mineralization of the bone resulting
in osteomalacia, with resultant bone pain, bone deformities, and frac-
ture. Excess FGF-23 also inhibits renal production of 1,25(OH)2D byacting on a FGF receptor (klotho) in the kidney and inhibiting renal con-
version of 25(OH)D to 1,25(OH)2D, which interferes with intestinal and
kidney phosphorus absorption, respectively. Low plasma phosphorus is
also known to stimulate renal production of 25-hydroxyvitmain D-1α
hydroxylase, resulting in conversion of 25 (OH)D to 1,25 (OH)2 D. How-
ever, in TIO, impaired renal phosphorus reabsorption lowers 1,25 (OH)2
D synthesis. Low or inappropriately normal serum levels of 1,25(OH)2 D
(in the setting of a lowphosphorus level) is themost commonbiochem-
ical feature of the disease. This patient also had hypercalcuria which we
suspect is related to hypoparathyroidism as evidenced by consistently
low PTH and low calcium since admission.
The diagnosis of TIO should be suspected from the clinical signs and
symptoms including acquired hypophosphatemia, osteomalacia, bone
fractures, and generalized muscle weakness in association with renal
phosphatewasting (but no other proximal tubular defects) and an inap-
propriately lowor normal plasma calcitriol concentration.Delayed diag-
nosed is typical in TIO, with times from symptom onset to diagnosis
reported to range from approximately 1.5–28 years with an average of
6.7 years (Jiang et al., 2012; de Jan et al., 2002). Male to female ratio is
approximately 1:1 with an average age of 42 years (Jiang et al., 2012).
Once a clinical diagnosis of TIO is made, the most challenging aspect
of the disease is localization of the FGF-23 producing tumor. A stepwise
approach that involves a thorough history, physical examination for pal-
pable tumors, and imaging should be undertaken. Selective venous
sampling, and tissue biopsy are seldom essential to discriminate a func-
tional mass when multiple suspicious lesions are discovered. Wide sur-
gical excision is important to avoid late recurrence andprovides the best
chance for complete cure. Radiofrequency ablation of the tumor has also
been described as an alternate method of treatment (Jadhav et al.,
2014).
Conventional imaging with CT, ultrasound, angiography and mag-
netic resonance imaging (MRI) have a high failure rate in localizing
84 E.G. Abate et al. / Bone Reports 5 (2016) 81–85the causative mesenchymal tumors because they are often small and
can be situated in obscure locations such as a distal extremity. For this
reason, whole body imaging is essential (de Jan et al., 2002). Tumors as-
sociated with TIO express somatostatin receptors 2 and 5 so
radiolabeled somatostatin analog scintigraphy (octreoscan) is frequent-
ly used to detect these tumors (de Jan et al., 2002; Jadhav et al., 2014; Rj
et al., 2013; Seufert et al., 2001). Jan de Beur et al reported 111Indium-
pentetreotide scintigraphy localized the offending tumor in 5 of 7 pa-
tients, whereas only 3 of the tumors were detected with conventional
imaging (de Jan et al., 2002). Tumors were located at various sites in-
cluding the ethmoid sinus, cranial fossa, humeral head, hand, and
lower leg. Once identiﬁed with an octreoscan, MRI was used for direct
anatomic visualization of the tumors, which were all later conﬁrmed
with surgery (de Jan et al., 2002). Rhee et al was also able to localize a
mesenchymal TIO tumor in the bone marrow of the femoral neck with
111indium-octreotide scintigraphy (Rhee et al., 2001). Octreoscan with
SPECT/CT has also been reported to improve localization (Rodrigues
et al., 2014). Unfortunately, the high sensitivity of octreotide scintigra-
phy is limited to tumors expressing somatostatin receptor subtypes 2
and 5, and this imaging technique cannot detect those tumors express-
ing subtypes 1 or 4 (de Jan et al., 2002; Rhee et al., 2001). Although less
sensitive than an octreoscan, whole body 18Fluorodeoxyglucose (FDG)
PET/CT is an alternate imaging modality that can be used to detect
FGF-23-secreting tumors. (PET/CT) allows for whole body functional
imaging together with CT for anatomic localization (Chong et al.,
2013). In a series of 31 patients, Chong et al reported that octreoscan
was able to accurately localize TIO mesenchymal tumors in 18/21 pa-
tients and exclude the disease in 7/9 patients. Conversely, FDG PET/CT
was able to accurately localize the tumor in only 14/21 patients
(Chong et al., 2013). Furthermore, octreoscan was superior in localiza-
tion of the tumor in 7/20 (35%) patients. Thus the authors suggested
that octreoscan should be the initial imaging modality used in the at-
tempt to localize a TIO-inducing tumor, with FDG PET/CT as an alternate
for scintigraphically occult tumors (Chong et al., 2013). Once the tumor
is detected by radiolabeled somatostatin scintigraphy, local imaging
with MRI of the suspicious site was used to provide a precise anatomic
location prior to surgery (Chong et al., 2013; Chong et al., 2011). Recent
reports investigating a hybrid of somatostatin receptor imaging with
PET/CT show promising results in the detection of tumors that are oth-
erwise occult by octreoscan or octreoscan-SPECT/CT (Rj et al., 2013;
Breer et al., 2014). Clifto-Bligh et al reported that Gallium-68 DOTA-
octreotide (DOTA-TATE) somatostatin receptor PET/CT hybrid imaging
localized tumors in 6/6 patients with histologically proven TIO (Rj
et al., 2013). Similarly, Breer et al reported5/5 patients had successful
detection of their tumor by using 68GaDTA-TATE PET/CT, whereas only
1/5 of these patients had tumor detected by 111indium octreotide scin-
tigraphy (Breer et al., 2014). Other imaging techniques that utilize so-
matostatin receptor analogs and selective venous sampling have also
been reported with varying degrees of success (Chong et al., 2013;
Chong et al., 2011; Breer et al., 2014; Sood et al., 2013; Jin et al., 2013;
Fukumoto, 2014; Agrawal et al., 2015). Frequently, multiple imaging
studies and continuous clinical monitoring are necessary to localize
these tumors, especially when small.
TIO has been described in association with adenocarcinomas of
the ovary, lung, prostate, colon and head/neck (Fatani et al., 2013;
Westerberg et al., 2012; Gandhi et al., 2012; Jiang et al., 2012;
Gardner et al., 2013; Hautmann et al., 2014; Lin et al., 2014;
Taylor et al., 1984; Lee et al., 2014; Ryan and Reiss, 1984;
Tarasova et al., 2013; Kominek et al., 2011; Luo et al., 2013;
Mathis et al., 2013). There has been one case report of a patient
with thyroid cancer presenting with TIO and bone metastasis. Al-
though this patient had a history of papillary thyroid cancer, test-
ing indicated that the patient's TIO and bone metastases were due
to a phosphaturic mesenchymal tumor (Morimoto et al., 2014). Ge-
netic mechanism by which tumors express FGF-23 is not well
known. Recent identiﬁcation of a novel FN1-FGFR1 genetic fusionwas reported (Lee et al., 2015). Future studies are needed for better
understanding.
In summary, a phosphorus level should be obtained during the eval-
uation of patientswith a clinical picture suspicious for osteomalacia. TIO
should be considered in patients with low serumphosphorus levels and
signs and symptoms of osteomalacia. Whole body imaging for tumor
detection is essential. The disease can be cured by successful resection
of the causative tumor with remineralization of bone and complete res-
olution of symptoms. This case report illustrates that anaplastic thyroid
cancer can potentially secrete FGF 23 and be a cause of TIO.Disclosure statement
The authors have nothing to disclose.Acknowledgment
No funding was received.References
Drezner, M.K., 2008. Phosphorus homeostasis and related disorders. In: Bilezikian, J.P.,
Raisz, L.G., Martin, T.J. (Eds.), Principles of Bone Biology. Academic Press, San Diego,
CA, U.S.A., pp. 465–486.
Mammen, J., de Beur SM, Jan, 2008. Tumor induced osteomalacia. In: Bilizikian, J.P., Raisz,
L.G., Martin, T.J. (Eds.), Principles of Bone Biology, third ed. Academic Press, San
Diego, CA, U.S.A., pp. 1549–1557.
Jonsson, K.B., Zahradnik, R., Larsson, T., White, K.E., Sugimoto, T., Imanishi, Y., et al., 2003.
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked
hypophosphatemia. N. Engl. J. Med. 348, 1656–1663.
Fatani, H.A., Sunbuli, M., Lai, S.Y., Bell, D., 2013. Phosphaturic mesenchymal tumor: a re-
port of 6 patients treated at a single institution and comparison with reported series.
Ann. Diagn. Pathol. 17 (4), 319–321.
Westerberg, P., Linde, T., Vanderschueren, D., Billen, J., Jans, I., Ljunggren, O., 2012. A case
of oncogenic osteomalacia illustrating the effect of ﬁbroblast growth factor 23 on
phosphate homeostasis. Clin. Kidney J. 0, 1–4.
Gandhi, G.Y., Shah, A.A., Wu, K.J., Gupta, V., Shoraka, A.R., 2012. Tumor-induced osteoma-
lacia caused by primary ﬁbroblast growth factor 23 secreting neoplasm in axial skel-
eton: a case report. Case Reports in Endocrinology 2012, 185454. http://dx.doi.org/
10.1155/2012/185454.
Jiang, Y., Xia, Wei-bo, Xiao-ping, X., Silva, C., M, L.I., Wang, O., et al., 2012. Tumor-induced
osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in
china: report of 39 cases and review of the literature. J. Bone Miner. Res. 27 (9),
1967–1975.
Gardner, K.H., Shon, W., Folpe, A.L., Wieland, C.N., Tebben, P.J., Baum, C.L., 2013. Tumor in-
duced osteomalacia resulting from primary cutaneous phosophaturic mesenchymal
tumor: a case and review of the medical literature. J. Cutan. Pathol. 40 (9), 780–784.
Hautmann, A.H., Schroeder, J., Wild, P., et al., 2014. Tumor-induced osteomalacia: in-
creased level of FGF-23 in a patient with a phosphaturic mesenchymal tumor at the
tibia expressing periostin. Case Reports in Endocrinology 2014, 729387. http://dx.
doi.org/10.1155/2014/729387.
Lin, H.A., Shih, S.R., Tseng, Y.T., Chen, C.H., Wy, Chiu, Hsu, C.Y., Tsai, K.S., 2014. Ovarian
cancer-related hypophosphatemia osteomalacia—a case report. J. Clin. Endocrinol.
Metab. 99 (12), 4403–4407.
Taylor, H.C., Fallon, M.D., Velasco, M.E., 1984. Oncogenic osteomalacia and inappropriate
antidiuretic hormone secretion due to oat-cell carcinoma. Ann. Intern. Med. 101
(6), 786–788.
Lee, Ek, Martinez, M.C., Blakely, K., Santos, K.D., Hoang, V.C., Chow, A., Emmeneger, U.,
2014. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with
castration-resistant prostate cancer presenting with severe hypophohatemia? Med.
Hypotheses 83 (4), 482–487.
Ryan, E.A., Reiss, E., 1984. Oncogenous osteomalacia. Review of the world literature of 42
cases and report of two new cases. Am. J. Med. 77 (3), 501–512.
Tarasova, V.D., Trepp-Carrasco, A.G., Thompson, R., Recker, R.R., Chong,W.H., Collins, M.T.,
Armas, L.A., 2013. Successful treatment of tumor-induced osteomalacia due to an in-
tracranial tumor by fractionated stereotactic radiotherapy. J. Clin. Endocrinol. Metab.
98 (11), 4267–4272.
Kominek, P., Starek, I., Geierova, M., Atousek, P., Zelenik, K., 2011. Phosphaturic mesen-
chymal tumour of the sinonasal area: case report and review of the literature. Head
Neck Oncol. 3 (16), 1–4.
Luo, L., Low, N., Vandervord, J., 2013. Mandibular phosphaturic mesenchymal tumor-
mixed connective tissue variant in a young girl. Cleft Palate Craniofac J. 50 (6),
751–753.
Mathis, D.A., Stehel, E.J., Beshay, J.E., Mickey, B.E., Folpe, A.L., Raisanen, J., 2013. Intracranial
phosphaturic mesenchymal tumors: report of 2 cases. J. Neurosurg. 118 (4), 903–907.
Shane, E., Parisien, M., Henderson, J.E., Dempster, D.W., Feldman, F., Hardy, M.A., et al.,
1997. Tumor-induced osteomalacia: clinical and basic studies. J. Bone Miner. Res.
12 (9), 1502–1511.
85E.G. Abate et al. / Bone Reports 5 (2016) 81–85Cai, Q., Hodgson, S.F., Kao, P.C., Lennon, V.A., Klee, G.G., Zinsmiester, A.R., Kumar, R., 1994.
Brief report: inhibition of renal phosphate transport by a tumor product in a patient
with oncogenic osteomalacia. N. Engl. J. Med. 330 (23), 1645–1649.
Carpenter TO, Imel, E.A., Holm, I.A., Jan de Beur, S.M., Insogna, K.L., 2011. A clinician's
guide to x-linked hypophosphatemia. J. Bone Miner. Res. 26 (7), 1381–1388.
Jan de Beur, S.M., Streeten, E.A., Civelek, A.C., McCarthy, E.F., Uribe, L., Marx, S.J., et al.,
2002. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lan-
cet 359, 761–763.
Jadhav, S., Kasaliwal, R., Shetty, N.S., Kulkarni, S., Rathod, K., Opat, B., et al., 2014. Radiofre-
quency ablation, an effectivemodality of treatment in tumor-induced osteomalacia: a
case series of three patients. J. Clin. Endocrinol. Metab. 99 (9), 3049–3054.
Rj, Clifton Bligh, Hofman, M.S., Duncan, E., lew, Si, Darnell, D., Clakson, A., et al., 2013. Im-
proving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET/
CT. J. Clin. Endocrinol. Metab. 98 (2), 687–694.
Seufert, J., Ebert, K., Muller, J., Eulert, J., Hendrich, C., Werner, E., et al., 2001. Octreotide
therapy for tumor induced osteomalacia. N. Engl. J. Med. 345 (26), 1883–1888.
Rhee, Y., Lee, J.D., Shin, K.H., Lee, H.C., Huh, K.B., Lim, S.K., 2001. Oncogenic osteomalacia
associated with mesenchymal tumour detected by indium-111 octreotide scintigra-
phy. Clin. Endocrinol. 54 (4), 551–554.
Rodrigues, N.R., Calich, A.L., Etchebehere, M., Ichiki, W.A., Pereira, F.P., Amstalden, E.M., de
Sa Etchebehere, E.C., 2014. Whole-body 99mTc-octreotide scintigraphy with SPECT/
CT to detect occult tumor inducing paraneoplastic osteomalacia. Clin. Nucl. Med.
00, 00-00.
Chong, W.H., Adreopoulou, P., Chen, C.C., Reynolds, J., Guthrie, L., Kelly, M., Garni, R.I.,
Bhhattacharyya, N., Boyce, A.M., El-Maouche, D., Crespo, D.O., Sherry, R., Change, R.,
Wodajo, F.M., Kletter, G.B., Dwyer, A., Collins, M.T., 2013. Tumor localization and bio-
chemical response to cure in tumor induced osteomalacia. J. Bone Miner. Res. 28 (6),
1386–1398.Chong,W.H., Yavuz, S., Patel, S.M., Chen, C.C., Collins, M.T., 2011. The importance of whole
body imaging in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 96 (12),
3599–3600.
Breer, S., Brunhorst, T., Beil, F.T., Peldschus, K., Heiland, M., Klutmann, S., et al., 2014. 68Ga
DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteo-
malacia but negative 111in-octreotide SPECT/CT. Bone 64, 222–227.
Sood, A., Agarwal, K., Shukla, J., Goel, R., Dhir, V., Bhattacharya, A., Rai Mittal, B., 2013. Bone
scintigraphic patterns in patients' of tumor induced osteomalacia. Indian J. Nucl. Med.
28 (2), 173–175.
Jin, X., Jing, H., Li, F., Zhuang, H., 2013. Osteomalcia-inducing renal clear cell carcinoma un-
covered by 99mTc-hydrazinonictinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigra-
phy. Clin. Nucl. Med. 38 (11), 922–924.
Fukumoto, S., 2014. Diagnostic modalities for FGF23-producing tumors in patients with
tumor induced osteomalacia. Endocrinol. Metab. 29 (2), 136–143.
Agrawal, K., Bhadada, S., Mittal, B.R., Shukla, J., Sood, A., Bhattacharya, A., Bhansali, A.,
2015. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor
causing oncogenic osteomalacia. Clin. Nucl. Med. 40 (1), e6–e10.
Morimoto, T., Takenaka, S., Hashimoto, N., Araki, N., Myoui, A., Yoskikawa, H., 2014.
Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases.
Oncol. Lett. 8 (1), 67–71.
Lee, J.C., Jeng, Y.M., Su, S.Y., Wu, C.T., Tsai, K.S., Lee, C.H., Lin, C.Y., Carter, J.M., Huang, J.W.,
Chen, S.H., Shih, S.R., Mariño-Enríquez, A., Chen, C.C., Folpe, A.L., Chang, Y.L., Liang,
C.W., 2015. Identiﬁcation of a novel FN1-FGFR1 genetic fusion as a frequent event
in phosphaturic mesenchymal tumour. J. Pathol. 235 (4), 539–545.
